The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Stock markets are not happy with Trump’s pick of Robert F. Kennedy Jr. to lead HHS. The SPDR Biotech ETF (XBI) lost 11.85% of its value in the last week. It traded at a low not seen since Japan’s ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...